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Available online 11 May 2016Background: Both Takotsubo cardiomyopathy (TTC) and reverse TTC (r-TTC) are characterized by reversible
regional wall motion abnormalities of the heart unrelated to coronary artery pathology. It remains unclear
whether and/or how r-TTC differs from TTC. Subarachnoid hemorrhage (SAH) is occasionally causative of
TTC/r-TTC, and this study was conducted to detect possible differences between TTC and r-TTC associated
with SAH.
Methods: A single-center retrospective study was conducted on 328 consecutive SAH patients. They rou-
tinely underwent transthoracic echocardiography (TTE), ECG, and measurements of plasma catechol-
amines and other cardiac biomarkers within 24 h of admission. Demographic, echocardiographic,
electrocardiographic and neurochemical proﬁles were compared between patients with TTC and r-TTC.
The diagnosis of TTC/r-TTC was based on the revised Mayo Clinic Criteria.
Results: Data of 21 SAH-induced TTC and 10 SAH-induced r-TTC patients admitted between January 2009
and December 2014 were analyzed. The patients with r-TTC were signiﬁcantly younger than those with
TTC (51.8± 10.9 vs. 63.5± 14.4 years, p=0.04). The former exhibited signiﬁcantly higher plasma epineph-
rine levels than the latter (809± 710 vs. 380 ± 391 pg/mL, p=0.04). Plasma norepinephrine levels did not
differ signiﬁcantly (2421± 1374 vs. 1724± 1591 pg/mL, p=0.25). No signiﬁcant differences were observed in
other demographic/physiologic variables, echocardiographic parameters, frequency of ECG abnormalities, and
90-daymortality.Moreover, none of the patientswho underwent a follow-up TTE exhibitedmorphologic change
from one type to the other.
Conclusions: The pathomechanisms in TTC and r-TTC may not be identical: however, distinguishing the two
conditions may not have great importance from the standpoint of clinical management and prognostication.
© 2016 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Transthoracic echocardiography1. Introduction
Takotsubo cardiomyopathy (TTC) is characterized by transient region-
al wall motion abnormalities (WMA) of the cardiac ventricle(s), and is
causally unrelated to coronary artery pathology [1]. Although there is no
universally accepted deﬁnition of TTC, the revised Mayo Clinic Criteria
have been used most commonly [1]. Those criteria state that TTC is tran-
sient hypokinesis, akinesis or dyskinesis of the left mid-ventricular seg-
ments with or without apical involvement [1]. Meanwhile, a TTC
variant, characterized by hypocontractile mid-ventricular segments and
a hypercontractile apex, is known and designated as either reverse TTCgery, Fujita Health University
.
eliability and freedom from bias
land Ltd. This is an open access articl(r-TTC) or inverted TTC [2–4]. Plasma catecholamine (epinephrine/
norepinephrine) levels are highly elevated in patients with both TTC
and r-TTC, and sympathetic nervous system over-activity has been impli-
cated as a common etiological mechanism [2–4]. Several authors have
attempted to identify potential differences between TTC and r-TTC unre-
lated to neurological diseases, and reported several differences [3,4].
Meanwhile, other authors have argued that TTC and r-TTC may be a
temporal evolution of the samedisease, based on patientswhodeveloped
r-TTC several weeks to months after an episode of typical TTC [5–8].
Therefore, the question of whether TTC is different from r-TTC has not
been answered fully. Reverse TTC is also known to develop in patients
with severe brain damage, particularly in those with aneurysmal sub-
arachnoid hemorrhage (SAH) [9–13]. However, only a few case reports
of SAH-induced r-TTC are available in the literature [9–13]. This study
was conducted to identify possible demographic, physiologic, echocardio-
graphic, electrocardiographic, and neurochemical differences between
TTC and r-TTC associated with SAH.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Comparison of demographic/physiologic variables between Takotsubo cardiomyopathy
and reverse Takotsubo cardiomyopathy after subarachnoid hemorrhage.
TTC (n = 21) r-TTC (n = 10) p-Value
Age (y) 63.5 ± 14.4 51.8 ± 10.9 0.04⁎
Male:female 7:14 7:3 0.12
Aneurysm locations MCA 7, ACoA 5, ICA 5,
VA 3, BA 1
VA 5, ACoA 4,
MCA 1
N/A
Grade IV/V SAH 18 (86%) 10 (100%) 0.53
Hypertension 11 (52%) 6 (60%) 1.00
Hyperlipidemia 2 (10%) 1 (10%) 1.00
Diabetes mellitus 1 (5%) 0 1.00
Current smoking 4 (19%) 4 (40%) 0.38
Systolic BP (mm Hg) 163 ± 57 131 ± 42 0.12
Diastolic BP (mm Hg) 96 ± 31 79 ± 20 0.13
Heart rate (bpm) 97 ± 29 95 ± 20 0.86
Pulmonary edema 5 (24%) 5 (50%) 0.22
Need for inotropic agents 8 (38%) 5 (50%) 0.70
90-day mortality 7 (33%) 5 (50%) 0.45
ACoA: anterior communicating artery; BA: basilar artery; BP: blood pressure; GCS:
Glasgow Coma Scale; ICA: internal carotid artery; MCA: middle cerebral artery; NA: not
applicable; r-TTC: reverse Takotsubo cardiomyopathy; TTC: Takotsubo cardiomyopathy;
VA: vertebral artery.
⁎ Statistically signiﬁcant.
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2.1. Patients
This was a retrospective analysis using data acquired prospectively
between January 2009 and December 2014. We prospectively per-
formed the following examinations on aneurysmal SAH patients: trans-
thoracic echocardiography (TTE), 12-lead ECG, and measurements of
plasma epinephrine/norepinephrine levels and those of other cardiac
biomarkers. All three examinations were completed within 24 h of ad-
mission. Follow-up TTEs were performed in selected patients, mostly
within 7 days of admission. The decision to perform a follow-up TTE
was at the discretion of the attending neuro-intensivist. All TTE images
were reviewed by a board-certiﬁed cardiologist (EW) and an experi-
enced ultrasound technician (KS). The diagnosis of TTC/r-TTC was
based on the revised Mayo Clinic Criteria [1] and dichotomization was
done jointly by the two authors (EW and KS). SAH severitywas evaluat-
ed using the World Federation of Neurosurgical Societies (WFNS) SAH
score [14]. Concomitant pulmonary edema was diagnosed clinically
[13]. Clinical outcomes are represented by 90-day mortality. This
study was approved by the internal review board of our institution,
and informed consent was obtained from patients or more often, from
their surrogates.
2.2. Echocardiographic/electrocardiographic evaluations
For acquisition of TTE, General Electric Vivid 7 (GE Healthcare,
Tokyo, Japan)was used. Experienced ultrasound technicians performed
all TTE procedures. Left ventricular (LV) dimensions, LV wall thickness,
and LV mass were measured according to the recommendations of the
American Society of Echocardiography, and LV mass was indexed to
body surface area [15,16]. A standard Doppler assessment of diastolic
function was performed according to the guidelines of the American
Society of Echocardiography [15,16]. Early diastolic (E) wave velocities
and atrial (A) wave velocities, and the E wave deceleration time were
measured using a pulse wave Doppler recording. Septal and lateral
mitral annular early diastolic velocities (E′)weremeasured from an api-
cal four-chamber view using off-line color tissue Doppler images. The
E = velocities from the lateral and septal annuli were averaged (E′),
and E/E′ was calculated to assess LV ﬁlling pressure. The following
images were obtained routinely to evaluate WMA: parasternal long
axis; parasternal short axis at the level of the mitral valve, papillary
muscles, and apex; apical two-, three-, and four-chamber; subcostal
four-chamber; and subcostal short axis. The 16 segment model of the
American Society of Echocardiography and the Regional Wall Motion
Score Index (RWMSI) were used for analysis [15,16]. The RWMSI was
calculated by averaging the scores for all 16 segments, and WMA was
deﬁned as a RWMSI ≥ 1.0 [15,16]. The frequencies of WMA were illus-
trated using the 16 segment model in the patients with TTC and r-TTC.
A board-certiﬁed cardiologist (EW)determined the presence or absence
of ST-segment changes, T-wave inversion, and the mean QTc interval
for the ECG evaluation. The frequencies of ST-segment change and T-
wave inversion, and mean QTc interval were compared between the
two groups.
2.3. Catecholamine/biomarker measurement
Plasma epinephrine and norepinephrine levels were measured by
high-performance liquid chromatography. The other cardiac bio-
markers measured were troponin I, B-type natriuretic peptide, white
blood cell count, and blood glucose levels.
2.4. Statistical analysis
Fisher's exact test was used to compare categorical variables, and
Student's t-test was used to compare continuous variables. Linearregression analysis was performed to evaluate the correlation between
plasmaepinephrine and norepinephrine levels. JMP software (SAS Insti-
tute, Cary, NC, USA) was used for all statistical analyses. Numerical data
are expressed as mean ± SD, and p b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Background data
A total of 328 consecutive patients with aneurysmal SAH underwent
TTE during the 6-year study period. Among them, 21 patients with TTC
and 10with r-TTCwere identiﬁed. All patientswith TTC/r-TTCwere eth-
nic Japanese. The demographic variables compared between the two
groups were: age, sex ratio, frequency of WFNS grade IV/V SAH and
presence of co-morbid diseases. Patients with r-TTC were signiﬁcantly
younger than those with TTC (51.8 ± 10.9 vs. 63.5 ± 14.4 years, p =
0.04) (Table 1). No signiﬁcant differences were observed in the other
demographic variables (Table 1). The physiological variables measured
in the emergency department, including systolic/diastolic blood pres-
sures, heart rates, and the frequency of pulmonary edema were com-
pared, but no signiﬁcant intergroup differences were observed
(Table 1). Similarly, no signiﬁcant difference was observed in the
frequency of patients who required the use of inotropics to maintain
systemic circulation (38% in TTC vs. 50% in r-TTC, p= 0.70). No signiﬁ-
cant difference was detected in 90-day mortality between the TTC and
r-TTC groups (33% vs. 50%, p= 0.45).
3.2. Echocardiographic/electrocardiographic ﬁndings
Marked differences in the frequencies of regional WMAs were re-
vealed in basal and apical segments by comparing the 16 segment
model between the patients with TTC and r-TTC (Fig. 1A, B). In contrast,
no signiﬁcant intergroup differences were detected in the echocardio-
graphic parameters for systolic/diastolic functions, including LV ejection
fraction, E value, E/A ratio or the E/E′ ratio (Table 2). Similarly, no signif-
icant intergroup difference was detected inmean RWMSI (Table 2). The
frequencies of ECG abnormalities were similar between the two groups
(Table 2).
Follow-up TTEs were obtained in 11 (52%) patients with TTC and in
ﬁve (50%) with r-TTC at a mean interval of 96 ± 43 h in the TTC and
91 ± 46 h in the r-TTC groups. As a result, residual WMAs were
Fig. 1. Comparison of the 16 segment model between Takotsubo cardiomyopathy (TTC,
A) and reverse Takotsubo cardiomyopathy (r-TTC, B) associated with subarachnoid
hemorrhage revealing that there were marked differences in the frequency of regional
wall motion abnormality in the apical and basal segments.
Table 3
Follow-up transthoracic echocardiography in Takotsubo cardiomyopathy and reverse
Takotsubo cardiomyopathy patients.
TTC (n = 21) r-TTC (n = 10) p-value
Follow-up TTE available 11/21 (52%) 5/10 (50%) 1.00
Interval between 1st and 2nd TTE (h) 96 ± 43 91 ± 46 0.84
Residual TCM/r-TCM in 2nd TTE 8/11 (73%) 2/5 (40%) 0.30
r-TTC: reverse Takotsubo cardiomyopathy; TTC: Takotsubo cardiomyopathy; TTE: trans-
thoracic echocardiography.
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r-TTC (Table 3). The frequencies of residual WMAs did not differ sig-
niﬁcantly (73% vs. 40%, p = 0.30). None of the 16 patients who
underwent follow-up TTE exhibited a morphological change from
one type to the other.Table 2
Comparison of echocardiographic and electrocardiographic parameters between
Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy.
TTC (n = 21) r-TTC (n = 10) p-value
LVEF (%) 43.7 ± 9.7 39.8 ± 11.3 0.33
LVIDd (mm) 44.5 ± 7.8 47.1 ± 5.1 0.36
LVIDs (mm) 33.3 ± 9.6 38.6 ± 4.8 0.14
LVMI (g/m2) 116.1 ± 41.8 83.8 ± 14.2 0.16
E (m/s) 69.5 ± 19.2 64.1 ± 18.2 0.48
A (m/s) 73.2 ± 24.8 65.9 ± 22.7 0.46
E/A 1.07 ± 0.51 1.04 ± 0.38 0.86
E′ (m/s) 5.52 ± 1.90 6.22 ± 1.78 0.35
E/E′ 13.7 ± 5.6 10.9 ± 4.5 0.19
DcT (ms) 189.7 ± 70.5 192.2 ± 61.5 0.93
RWMSI 1.77 ± 0.35 1.71 ± 0.38 0.65
ST segment change 13/21 (62%) 7/10 (70%) 1.00
T-wave inversion 6/21 (29%) 1/10 (10%) 0.38
QTc (ms) 476 ± 5 463 ± 4 0.48
DcT: deceleration time; LVEF: left ventricular ejection fraction; LVIDd: left ventricular in-
ternal dimension, diastole; LVIDs: left ventricular internal dimension, systole; LVMI: left
ventricular mass index; RWMSI: Regional Wall Motion Score Index; TTC: Takotsubo car-
diomyopathy; r-TTC: reverse Takotsubo cardiomyopathy.3.3. Catecholamine/biomarker measurement
Plasma epinephrine levels (pg/mL) were 380 ± 391 in the patients
with TTC and 809± 710 in those with r-TTC (p=0.04, Fig. 2A). Plasma
norepinephrine levels (pg/mL) were 1724 ± 1591 in TTC and 2421 ±
1374 in r-TTC, and there was no signiﬁcant difference (p = 0.25,
Fig. 2B). The linear regression analysis showed that plasma epinephrine
and norepinephrine levels were not correlated in the patients with
TTC (R = 0.18, p = 0.447) (Fig. 3A) and weakly correlated in those
with r-TTC (R = 0.57, p = 0.09) (Fig. 3B). No signiﬁcant differences
were detected in the levels of the other biomarkers (Table 4).4. Discussion
It is widely accepted that TTC and r-TTC share many characteristics.
However, it remains controversial whether r-TTC actually differs
demographically, prognostically and neurochemically from TTC. Several
authors have reported that patientswith r-TTC are signiﬁcantly younger
and have a higher prevalence of triggering stress [3,4]. In contrast, thereFig. 2. Plasma epinephrine levels (pg/mL) were 380 ± 391 in Takotsubo cardiomyopathy
(TTC) and 809 ± 710 in reverse Takotsubo cardiomyopathy (r-TTC) patients (A). The
difference was statistically signiﬁcant (p= 0.04). Plasma norepinephrine levels (pg/mL)
were 1724 ± 1591 for TTC and 2421 ± 1374 for r-TTC patients (B). The difference was
not statistically signiﬁcant (p= 0.25).
Fig. 3. Linear regression analysis showing that the plasma epinephrine and
norepinephrine levels were not correlated in the 21 TTC patients (0.18, p= 0.447) (A).
The plasma epinephrine and norepinephrine levels were weakly correlated in the 10 r-
TTC patients (R = 0.57, p= 0.09) (B).
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suggesting that TTC and r-TTC may be a temporal evolution of the
same disease [5–8]. Most of those studies were performed on patients
with idiopathic TTC, i.e., those without neurological disease or pheo-
chromocytoma. However, virtually no study has evaluated the potential
differences between TTC and r-TTC in patients with SAH. In this regard,
our study may be one of the ﬁrst to report the presence of substantial
differences between these two conditions. This study is also unique in
that a team of cardiologists, ultrasound technicians and neurosurgeons
jointly evaluated the differences between TTC and r-TTC. The frequency
of r-TTC in patients without neurological disease seems to be low; Song
et al. reported that the ratio of r-TTC vs. other TTC is approximately 1:4.
[3]. In contrast, r-TTC in patients with SAHmay occur more commonly,
considering a higher r-TTC:TTC ratio of approximately 1:2 in our cohort.
We found that patients with r-TTC were signiﬁcantly younger than
those with TTC (Table 1), which is consistent with previous studies on
idiopathic TTC [3,4]. The neurochemical proﬁles also differed between
the patients with TTC and r-TTC (Figs. 2, 3). No cases of crossover,
i.e., morphological changes from one type to the other, were found onTable 4
Comparison of cardiac biomarker levels between Takotsubo cardiomyopathy and reverse
Takotsubo cardiomyopathy.
TTC (n = 21) r-TTC (n = 10) p-Value
Troponin I (ng/mL) 2.21 ± 3.28 0.87 ± 0.97 0.28
BNP (pg/mL) 214.8 ± 306.8 157.2 ± 192.6 0.71
WBC (×109/L) 13.6 ± 5.3 14.3 ± 5.9 0.77
Blood glucose (mg/dL) 198.5 ± 56.6 183.2 ± 69.5 0.53
BNP: B-type natriuretic peptide; r-TTC: reverse Takotsubo cardiomyopathy; TTC:
Takotsubo cardiomyopathy; WBC: white blood cells.the second follow-up TTE study. Therefore, TTC and r-TTC may not be
identical neurochemically, at least in patients with SAH. From the view-
point of clinical management, however, there may be few differences
between TTC and r-TTC, except that the latter tend to bemore hypoten-
sive (Table 1): neither 90-day mortality nor the need for inotropic
agents differed signiﬁcantly. Similarly, few differences were found in
the TTE parameters or ECG ﬁndings (Table 2), despite marked morpho-
logical differences on TTE. Therefore, distinguishing TTC from r-TTCmay
not be very important to neurosurgeons, cardiologists or intensivists for
planning the treatment strategy or predicting outcomes in SAHpatients.
The follow-up TTE study results indicated that r-TTC may resolve more
rapidly than TTC, as WMA had resolved in 60% of r-TTC patients on
the second TTE performed 4 days after the ﬁrst. In contrast, only
27%of TTC patients exhibitednormalized cardiacwallmotion.No signif-
icant differences were observed because of the small number of
patients, and it remains to be seen whether speed of recovery truly
differs between patients with TTC and r-TTC.
Among many neurochemical substances etiologically associated
with cardiac WMA, epinephrine and norepinephrine may be the most
important [12]. As plasma levels of both catecholamines are highly
elevated after stressful events, such as aneurysm rupture, it is difﬁcult
to determinewhich catecholamine plays a more active role in the path-
ogenesis of TTC and/or r-TTC. Unintentional (frequently iatrogenic) epi-
nephrine administration may provide unique insight, because many
cases of iatrogenic r-TTChave been associatedwith exogenous epineph-
rine administration in the literature [17–24]. Our ﬁnding of extremely
elevated epinephrine levels in patients with r-TTC may also support
its etiological role. The higher epinephrine–norepinephrine correlation
coefﬁcient in patients with r-TTC compared to those with TTC (Fig. 3A,
B) is also reasonable. However, our ﬁndings may not be explained by
the working hypothesis that a difference in the distribution of β1/β2-
adrenoceptors between the apex and base, with denser β2-
adrenoceptor distribution in the apex, is the reason for the greater
contractile response to epinephrine in the apical myocardium with
subsequent apical stunning [25]: according to this hypothesis, higher
epinephrine levels would lead to typical TTC rather than to r-TTC [25].
Further clinical and experimental studies are warranted to elucidate
the role of each catecholamine and its adrenoceptor in the pathogenesis
of TTC and r-TTC [26].
Several limitations of this study should be mentioned. First, this
was a retrospective observational study; thus, it is impossible to prove
the causality of elevated epinephrine in the pathogenesis of r-TTC.
Second, dichotomization into TTC and r-TTCmay have been too simplis-
tic, considering that as many as four TTC variants have been proposed
[27]. Although this dichotomization has been adopted by several
authors, categorical overlap might have occurred, particularly involving
themid-ventricular segments. Third, the number of patients was small:
given that both conditions have low incidences making it difﬁcult to
accumulate an adequate number of samples, it may be important to
establish national/international TTC registries [28]. Fourth, because of
the short half-life of epinephrine, the epinephrine/norepinephrine
coefﬁcient can vary substantially with the timing of blood sample
collection [29]. Finally, the follow-up TTEs were conducted in only half
of the patients, and the interval between the ﬁrst and second TTEs
may have been too short; therefore, it may be too early to conclude
that a morphological change from one type to the other does not
occur in patients with SAH.
5. Conclusion
Patients with SAH-induced r-TTCwere signiﬁcantly younger and ex-
hibited higher plasma epinephrine levels than those with SAH-induced
TTC. These results suggest that the pathomechanisms of the two
conditions may not be identical. However, distinguishing between TTC
and r-TTC in patients with SAH may not have great importance from
the standpoint of clinical management and prognostication.
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